Published in Drugs on June 28, 2017
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Origins and Mechanisms of miRNAs and siRNAs. Cell (2009) 20.77
Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 18.88
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
Toll-like receptors in the induction of the innate immune response. Nature (2000) 12.23
T cell exhaustion. Nat Immunol (2011) 11.08
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine (2012) 6.01
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med (1996) 3.60
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology (2012) 3.13
Adenoviruses as vaccine vectors. Mol Ther (2004) 3.09
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther (2008) 2.90
Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science (2003) 2.84
HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology (2008) 2.84
Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut (2013) 2.74
PD-1 signaling in primary T cells. Immunol Rev (2009) 2.66
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Jump-starting the immune system: prime-boosting comes of age. Trends Immunol (2004) 2.61
The cyclophilins. Genome Biol (2005) 2.58
Therapeutic genome editing: prospects and challenges. Nat Med (2015) 2.42
Control of cccDNA function in hepatitis B virus infection. J Hepatol (2009) 2.41
DNA vaccines: progress and challenges. J Immunol (2005) 2.34
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut (2014) 2.28
The immune response during hepatitis B virus infection. J Gen Virol (2006) 2.21
GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology (2013) 2.14
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol (2001) 1.98
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol (2012) 1.86
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (2004) 1.83
Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A (1997) 1.78
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology (2013) 1.77
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A (2009) 1.74
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol (2009) 1.72
Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72
Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med (2002) 1.66
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology (2009) 1.65
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 1.59
Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (2009) 1.59
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol (2010) 1.54
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology (2011) 1.49
The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids (2014) 1.46
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther (2013) 1.42
IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome. PLoS One (2015) 1.40
Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut (1996) 1.38
Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol (2013) 1.37
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine (2005) 1.33
Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids (2014) 1.33
Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology (2009) 1.32
Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol (2001) 1.31
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother (2012) 1.31
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol (2012) 1.29
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology (2014) 1.29
Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology (2004) 1.28
Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther (2006) 1.25
Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology (2012) 1.25
Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One (2012) 1.23
Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol (2013) 1.22
Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol (2010) 1.21
Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology (2014) 1.20
Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology (2014) 1.19
Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods (1990) 1.18
Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog (2013) 1.16
Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology (2005) 1.15
Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest (2014) 1.13
Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12
Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A (2014) 1.11
Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther (2010) 1.10
Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res (2013) 1.10
An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther (2013) 1.10
Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog (2014) 1.09
T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis (2015) 1.09
The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol (1994) 1.09
Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother (2013) 1.08
Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett (2003) 1.08
Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells. J Virol (2001) 1.06
RNAi for treating hepatitis B viral infection. Pharm Res (2007) 1.05
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? Neth J Med (2006) 1.04
Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol (2014) 1.04
AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One (2014) 1.04
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology (2014) 1.04
Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet (1995) 1.03
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci (2014) 1.02
Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. Hepatology (2003) 1.01
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res (2006) 1.01
Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology (2015) 1.01
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol (2015) 1.00
Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Res (2015) 1.00
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99